Microenvironmental support for cell delivery to the inner ear

Schulze, Jessika; Sasse, S.; Prenzler, Nils; Staecker, Hinrich; Mellott, Adam J.; Roemer, Ariane; Ďurišin, Martin; Lenarz, Thomas; Warnecke, Athanasia

doi:10.1016/j.heares.2018.06.015

Cited by 4 publications

(8 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(iii) Coating the electrode carrier with cells producing therapeutic molecules. The advantage of this approach is to be a source of complex macromolecules (56)(57)(58)(59)(60). However, stem cells are limited to the production of bioactive substances that are naturally produced in the body.…”

Section: Discussionmentioning

confidence: 99%

Long-Term in vivo Release Profile of Dexamethasone-Loaded Silicone Rods Implanted Into the Cochlea of Guinea Pigs

et al. 2020

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Long-Term in vivo Release Profile of Dexamethasone-Loaded Silicone Rods Implanted Into the Cochlea of Guinea Pigs

et al. 2020

View full text Add to dashboard Cite

show abstract

Section: Hipsc-otic Cell Derivatives For a Cell Therapy Approachmentioning

confidence: 99%

“…This transplantation paradigm resulted in glutamate transporter (VGlut1) expression in more than 50% of the transplanted ONPs, yet only about 2% of cells survived 2 weeks post‐transplantation. Furthermore, pharmacological agents that mimic the effects of matrix scaffolds (ie, heparan sulfate analogues) have been demonstrated to play an important role in promoting cell delivery to the inner ear of guinea pigs or to decellularized cochleae 69 . Another study demonstrated that by using self‐assembling peptide amphiphile molecules to create a niche for hESC‐derived ONPs enhanced neural survival and differentiation after transplantation into X‐SCID rat cochlea 70 .…”

Section: Hipsc‐otic Cell Derivatives For a Cell Therapy Approachmentioning

confidence: 99%

“…Furthermore, pharmacological agents that mimic the effects of matrix scaffolds (ie, heparan sulfate analogues) have been demonstrated to play an important role in promoting cell delivery to the inner ear of guinea pigs or to decellularized cochleae. 69 Another study demonstrated that by using self‐assembling peptide amphiphile molecules to create a niche for hESC‐derived ONPs enhanced neural survival and differentiation after transplantation into X‐SCID rat cochlea. 70 The same group used 3D‐spheroid system, ECM (ie, nanofibrillar cellulose hydrogel), and a neurotrophic factor delivery to artificially create a stem cell niche that allowed hESC‐derived ONP engraftment as well as neuronal differentiation.…”

Section: Hipsc‐otic Cell Derivatives For a Cell Therapy Approachmentioning

confidence: 99%

See 1 more Smart Citation

A human induced pluripotent stem cell-based modular platform to challenge sensorineural hearing loss

2021

View full text Add to dashboard Cite

The sense of hearing depends on a specialized sensory organ in the inner ear, called the cochlea, which contains the auditory hair cells (HCs). Noise trauma, infections, genetic factors, side effects of ototoxic drugs (ie, some antibiotics and chemotherapeutics), or simply aging lead to the loss of HCs and their associated primary neurons. This results in irreversible sensorineural hearing loss (SNHL) as in mammals, including humans; the inner ear lacks the capacity to regenerate HCs and spiral ganglion neurons. SNHL is a major global health problem affecting millions of people worldwide and provides a growing concern in the aging population. To date, treatment options are limited to hearing aids and cochlear implants. A major bottleneck for development of new therapies for SNHL is associated to the lack of human otic cell bioassays. Human induced pluripotent stem cells (hiPSCs) can be induced in two-dimensional and three-dimensional otic cells in vitro models that can generate inner ear progenitors and sensory HCs and could be a promising preclinical platform from which to work toward restoring SNHL. We review the potential applications of hiPSCs in the various biological approaches, including disease modeling, bioengineering, drug testing, and autologous stem cell based-cell therapy, that offer opportunities to understand the pathogenic mechanisms of SNHL and identify novel therapeutic strategies.

show abstract

“…Feasibility and safety of this approach has recently been tested in a human trial (Roemer et al, 2016). Further work has highlighted the opportunity to modulate inner ear cell behaviour following local delivery of mesenchymal stromal cells (Schulze et al, 2018).…”

Section: Stem Cellsmentioning

confidence: 99%

Early phase trials of novel hearing therapeutics: Avenues and opportunities

Schilder

Mandavia

et al. 2019

Hearing Research

View full text Add to dashboard Cite

Novel hearing therapeutics are rapidly progressing along the innovation pathway and into the clinical trial domain. Because these trials are new to the hearing community, they come with challenges in terms of trial design, regulation and delivery. In this paper, we address the key scientific and operational issues and outline the opportunities for interdisciplinary and international collaboration these trials offer. Vital to the future successful implementation of these therapeutics is to evaluate their potential for adoption into healthcare systems, including consideration of their health economic value. This requires early engagement with all stakeholder groups along the hearing innovation pathway.

show abstract

Microenvironmental support for cell delivery to the inner ear

Cited by 4 publications

References 65 publications

Long-Term in vivo Release Profile of Dexamethasone-Loaded Silicone Rods Implanted Into the Cochlea of Guinea Pigs

Long-Term in vivo Release Profile of Dexamethasone-Loaded Silicone Rods Implanted Into the Cochlea of Guinea Pigs

A human induced pluripotent stem cell-based modular platform to challenge sensorineural hearing loss

Early phase trials of novel hearing therapeutics: Avenues and opportunities

Contact Info

Product

Resources

About